San Diego, CA (May 8, 2009) – BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today an expansion of its research grants to support life sciences research during the current economic downturn.
“We have expanded the BD Biosciences Research Grant Program to provide a greater pool of funding and an increased number of grants that may offer a lifeline to some of the numerous projects being halted or delayed because of resource cuts,” said Robert Balderas, Vice President of Biological Sciences, BD Biosciences. “It will offer selected life science researchers needed support to carry out their work that may lead to tomorrow’s biomedical breakthroughs.”
The new BD Biosciences Research Grant Program will award 14 scientists with a total of $140,000 worth of research reagents over the next 12 months. An independent panel of judges will review applications from U.S. scientists, and grants will be awarded in two cycles (October 2009 and May 2010) to help cover year-round research needs. Grant applications should focus on research in one of seven core areas: stem cell, multicolor flow cytometry, cell signaling, cancer, immune function, infectious diseases and neurosciences.
BD Biosciences will accept grant applications for the first awards cycle until August 15, 2009. Additional information about the grant program, including the application process and deadlines, is available at www.bdbiosciences.com/grant.
About the BD Biosciences Research Grant Program
BD Biosciences’ Research Grant Program aims to reward and enable important research by providing vital funding for scientists pursuing innovative experiments to advance the scientific understanding of disease. The grant submissions are judged by a distinguished research panel of non-affiliated scientists. Through its grant program, BD Biosciences supports innovation in research and development as well as help enable the next generation of scientific breakthroughs.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.
